J
Jean Haensler
Researcher at University of California, San Francisco
Publications - 10
Citations - 1359
Jean Haensler is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Immunology. The author has an hindex of 2, co-authored 6 publications receiving 1316 citations.
Papers
More filters
Journal ArticleDOI
Polyamidoamine cascade polymers mediate efficient transfection of cells in culture
Jean Haensler,Francis C. Szoka +1 more
TL;DR: It is shown, using luciferase and beta-galactosidase containing plasmids, that dendrimers mediate high efficiency transfection of a variety of suspension and adherent cultured mammalian cells.
Journal ArticleDOI
Synthesis and characterization of a trigalactosylated bisacridine compound to target DNA to hepatocytes
Jean Haensler,Francis C. Szoka +1 more
TL;DR: Three bisacridine intercalators containing a galactose residue(s) to target DNA to cell surface receptors for use in gene-delivery systems and binding of the (Gal-6)3Lys2-bA-DNA to the hepatocytes could be blocked by asialoorosomucoid.
Journal ArticleDOI
An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates
Manon Ripoll,Marie-Clotilde Bernard,Céline Vaure,Emilie Bazin,Sylvie Commandeur,Vladimir Perkov,Katia Lemdani,Marie-Claire Nicolaï,Patrick Bonifassi,Antoine Kichler,Benoît Frisch,Jean Haensler +11 more
TL;DR: In this paper , a novel imidazole modified lipid, DOG-IM4, was proposed to improve the thermostability of mRNA/LNP vaccines by combining with standard helper lipids.
Patent
Selbst zusammenbaubares system zur verabreichung von polynukleotiden
Francis C. Szoka,Jean Haensler +1 more
Journal ArticleDOI
Nonclinical safety assessments of a novel synthetic toll-like receptor 4 agonist and saponin based adjuvant.
TL;DR: In this paper , a full nonclinical safety package was performed to support the clinical use of SPA14, a novel liposome-based vaccine adjuvant containing the synthetic toll-like receptor 4 agonist E6020 and saponin QS21.